Among them, HBG1 and HBG2 had the highest average fold-change (FC) when the genes were ranked using logFC (Table S5), and were previously implicated in better AZA treatment outcome in MDS/AML patients [30]. This evidence concerns the gene HBG1 and myelodysplastic syndrome.